Advertisement

Breast Cancer

  • Nicholas G. ZaorskyEmail author
  • Daniel M. Trifiletti
  • Jennifer Rosenberg
Chapter

Abstract

This chapter discusses the general management of patients with breast cancers, with special focus on principles that guide radiotherapy management. Several key components of trimodality care and accelerated partial breast irradiation (APBI) are discussed.

Keywords

Breast Carcinoma Ductal Phyllodes DCIS 

References

  1. 1.
    Ho AL, Bovill ES, Macadam SA, et al. Postmastectomy radiation therapy after immediate two-stage tissue expander/implant breast reconstruction: a University of British Columbia perspective. Plast Reconstr Surg. 2014;134:1e–10e.CrossRefGoogle Scholar
  2. 2.
    Borgen PI, Senie RT, McKinnon WM, et al. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997;4:385–8.CrossRefGoogle Scholar
  3. 3.
    Botteri E, Bagnardi V, Rotmensz N, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol. 2010;21:723–8.CrossRefGoogle Scholar
  4. 4.
    Amin MB, Edge SB, Byrd DR, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 8th ed. New York, NY: Springer; 2017.CrossRefGoogle Scholar
  5. 5.
    Chagpar AB, Killelea BK, Tsangaris TN, et al. A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med. 2015;373:503–10.CrossRefGoogle Scholar
  6. 6.
    Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.CrossRefGoogle Scholar
  7. 7.
    Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first–line therapy for HR–positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48.CrossRefGoogle Scholar
  8. 8.
    Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.CrossRefGoogle Scholar
  9. 9.
    Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18.CrossRefGoogle Scholar
  10. 10.
    Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.CrossRefGoogle Scholar
  11. 11.
    Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112:1001–10.CrossRefGoogle Scholar
  12. 12.
    Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967–75.CrossRefGoogle Scholar
  13. 13.
    Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387:849–56.CrossRefGoogle Scholar
  14. 14.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.CrossRefGoogle Scholar
  15. 15.
    Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase–inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19.CrossRefGoogle Scholar
  16. 16.
    Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366–73.CrossRefGoogle Scholar
  17. 17.
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41.CrossRefGoogle Scholar
  18. 18.
    Martinez-Monge R, Gomez-Iturriaga A, Cambeiro M, et al. Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy. 2009;8:26–33.CrossRefGoogle Scholar
  19. 19.
    Cook B DT. Wikibooks radiation oncology. https://en.wikibooks.org/wiki/Radiation_Oncology. Accessed April 2018.
  20. 20.
    Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York, NY: Springer; 2010.Google Scholar
  21. 21.
    Hansen ERM. Handbook of evidence-based radiation oncology. 2nd ed: Springer; 2010.Google Scholar
  22. 22.
    Hristov BLS, Christodouleas JP. Radiation oncology - a question based review. 2nd ed: LWW; 2014.Google Scholar
  23. 23.
    Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.CrossRefGoogle Scholar
  24. 24.
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.CrossRefGoogle Scholar
  25. 25.
    Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26:1247–52.CrossRefGoogle Scholar
  26. 26.
    Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.CrossRefGoogle Scholar
  27. 27.
    Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.CrossRefGoogle Scholar
  28. 28.
    Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–20.CrossRefGoogle Scholar
  29. 29.
    Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105:701–10.CrossRefGoogle Scholar
  30. 30.
    Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.CrossRefGoogle Scholar
  31. 31.
    Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974–9.CrossRefGoogle Scholar
  32. 32.
    McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33:709–15.CrossRefGoogle Scholar
  33. 33.
    Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031–6.CrossRefGoogle Scholar
  34. 34.
    Fisher ER, Sass R, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986;57:197–208.CrossRefGoogle Scholar
  35. 35.
    Fisher ER, Leeming R, Anderson S, et al. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol. 1991;47:139–47.CrossRefGoogle Scholar
  36. 36.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefGoogle Scholar
  37. 37.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefGoogle Scholar
  38. 38.
    Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–65.CrossRefGoogle Scholar
  39. 39.
    Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23:1934–40.CrossRefGoogle Scholar
  40. 40.
    Bentzen SM, Agrawal RK, Aird EG, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–41.CrossRefGoogle Scholar
  41. 41.
    Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26:791–7.CrossRefGoogle Scholar
  42. 42.
    Cascinelli N, Greco M, Bufalino R, et al. Prognosis of breast cancer with axillary node metastases after surgical treatment only. Eur J Cancer Clin Oncol. 1987;23:795–9.CrossRefGoogle Scholar
  43. 43.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefGoogle Scholar
  44. 44.
    Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.CrossRefGoogle Scholar
  45. 45.
    Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.CrossRefGoogle Scholar
  46. 46.
    Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.CrossRefGoogle Scholar
  47. 47.
    Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.CrossRefGoogle Scholar
  48. 48.
    Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefGoogle Scholar
  49. 49.
    Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15:963–8.CrossRefGoogle Scholar
  50. 50.
    van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.CrossRefGoogle Scholar
  51. 51.
    Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996;35:731–44.CrossRefGoogle Scholar
  52. 52.
    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefGoogle Scholar
  53. 53.
    Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefGoogle Scholar
  54. 54.
    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefGoogle Scholar
  55. 55.
    Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.CrossRefGoogle Scholar
  56. 56.
    Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.CrossRefGoogle Scholar
  57. 57.
    Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of cancer study of 61 patients. Cancer. 2001;91:472–7.CrossRefGoogle Scholar
  58. 58.
    van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84.CrossRefGoogle Scholar
  59. 59.
    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefGoogle Scholar
  60. 60.
    Strnad V, Ott OJ. Hildebrandt G, et al: 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–38.CrossRefGoogle Scholar
  61. 61.
    Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRefGoogle Scholar
  62. 62.
    Formenti SC, Hsu H, Fenton-Kerimian M, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients. Int J Radiat Oncol Biol Phys. 2012;84:606–11.CrossRefGoogle Scholar
  63. 63.
    Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9.  https://doi.org/10.1016/j.prro.2016.09.007.CrossRefGoogle Scholar
  64. 64.
    Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys. 2001;50:397–403.CrossRefGoogle Scholar
  65. 65.
    Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.CrossRefGoogle Scholar
  66. 66.
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431–9.CrossRefGoogle Scholar
  67. 67.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–90.CrossRefGoogle Scholar
  68. 68.
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673–82.CrossRefGoogle Scholar
  69. 69.
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.CrossRefGoogle Scholar
  70. 70.
    Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–96.CrossRefGoogle Scholar
  71. 71.
    McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRefGoogle Scholar
  72. 72.
    Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–5.CrossRefGoogle Scholar
  73. 73.
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med. 1997;337:949–55.CrossRefGoogle Scholar
  74. 74.
    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.CrossRefGoogle Scholar
  75. 75.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.CrossRefGoogle Scholar
  76. 76.
    Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–47.CrossRefGoogle Scholar
  77. 77.
    Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001:96–102.CrossRefGoogle Scholar
  78. 78.
    Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996;334:1356–61.CrossRefGoogle Scholar
  79. 79.
    Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2004;4:415–9.CrossRefGoogle Scholar
  80. 80.
    Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47:1191–200.CrossRefGoogle Scholar
  81. 81.
    Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:474–84.CrossRefGoogle Scholar
  82. 82.
    Haagensen CD, Stout AP. Carcinoma of the breast: II. Criteria of operability. Ann Surg. 1943;118:859–70.CrossRefGoogle Scholar
  83. 83.
    Pezner RD, Schultheiss TE, Paz IB. Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys. 2008;71:710–3.CrossRefGoogle Scholar
  84. 84.
    National Comprehensive Cancer Network Clinical Practice Guidelines. Breast cancer v 2.2016.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicholas G. Zaorsky
    • 1
    Email author
  • Daniel M. Trifiletti
    • 2
  • Jennifer Rosenberg
    • 1
  1. 1.Penn State Cancer InstituteHersheyUSA
  2. 2.Mayo ClinicJacksonvilleUSA

Personalised recommendations